Napryeyenko, 2007, [21] [91]

Mild to moderate dementia with neuropsychiatric features

Multicenter, randomized, placebo- controlled

395 (198 GBE treatment group and 197 placebo group); i.d.

≥50 years (no upper limit); mean age = 65 ± 8 years for GBE treatment group and 63 ± 8 years for placebo group

2 × 120 mg = 240 mg EGb 761/day (vs. placebo) for 22 weeks, no information on follow-up

Secondary outcome variable: change in patient self-ratings of presence and severity of dizziness and tinnitus using 11-point box scales.

Dizziness: Change from baseline at week 22 for the dizziness 11-point box scale was −1.7 for the GBE group and −0.3 for the placebo group; p < 0.001; mean reduction difference in dizziness severity in favor of GBE treated patients compared to placebo was statistically meaningful (−1.93 [95% CI: −2.24, −1.62])

Tinnitus: Change from baseline at week 22 for the tinnitus 11-point box scale was −1.1 for the GBE group and −0.0 for the placebo group; p < 0.001; mean reduction difference in tinnitus severity in favor of GBE treated patients compared to placebo was statistically meaningful (−1.96 [95% CI: −2.35, −1.57]).

Nikolova, 2013, [21] [92] [article in Russian]

Mild to moderate dementia

Randomized, placebo- controlled, double-blind

408 (203 received GBE treatment and 205 received placebo); i.d.

Not specified

240 mg EGb 761/ day (vs. placebo) for 22 weeks, no information on follow-up

Secondary outcomes variable: change in 11-point box scales for the rating of presence and severity of dizziness and tinnitus from baseline.

Dizziness: Mean reduction difference in tinnitus severity in favor of GBE treated patients compared to placebo was statistically meaningful (−0.29 [95% CI: −0.88, −0.30])

Tinnitus: Mean reduction difference in tinnitus severity in favor of GBE treated patients compared to placebo was statistically meaningful (−0.66 [95% CI: −1.23, −0.09]).